Frontiers in Pediatrics (Jul 2023)

Serum IgE levels are a risk factor with prognosis of pediatric minimal change disease

  • Tingting Han,
  • Tingting Han,
  • Mei Xue,
  • Yafei Guan,
  • Yafei Guan,
  • Tao Ju,
  • Kaili Shi,
  • Mengzhen Fu,
  • Lili Jia,
  • Chunlin Gao,
  • Chunlin Gao,
  • Zhengkun Xia,
  • Zhengkun Xia

DOI
https://doi.org/10.3389/fped.2023.1234655
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundMinimal change disease (MCD) is one of the most common primary glomerular disorders with high serum IgE levels. This study was aimed to investigate the clinical features of different serum IgE levels in pediatric MCD and evaluate the prognostic significance of serum IgE levels with regard to remission and relapse in pediatric cohort.MethodsThis study enrolled 142 new-onset children diagnosed with biopsy-proven MCD from January 2010 to December 2021 at the Jinling Hospital in Nanjing, China. These cases were divided into three groups according to serum IgE levels. MCD patients’ demographics, clinical parameters, and follow-up data were collected and analyzed. The primary and secondary outcomes were defined as the time to the first complete remission (CR) and the first relapse.ResultsThe results manifested that 85.2% (121/142) of MCD children had high serum IgE levels (IgE > 90.0 IU/ml). A total of 142 patients were divided into the normal-, low-, and high-IgE groups based on the normal reference value level (90.0 IU/ml) and median serum IgE level (597.5 IU/ml). The high-IgE group had a significantly lower cumulative rate of the first CR (log-rank, P = 0.032) and a higher rate of the first relapse (log-rank, P = 0.033) than the normal-IgE and low-IgE groups. Multivariate Cox analysis showed that IgE ≥597.5 IU/ml was independently associated with the delayed first CR [hazard ratio (HR) = 0.566, 95% confidence interval (CI) = 0.330–0.972, P = 0.039] and the early first relapse (HR = 2.767, 95% CI = 1.150–6.660, P = 0.023).ConclusionsSerum IgE levels were an independent correlation factor for pediatric MCD-delayed remissions and early relapses.

Keywords